Tag: KDC-MN-245

  • Topiramate

    Sulfamate-substituted monosaccharide / multifactorial anticonvulsant

    A sulfamate-substituted monosaccharide anticonvulsant with broad mechanism (sodium channels, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition); used for migraine prophylaxis and weight loss.

    Abstract

    Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; CAS 97240-79-4; molecular formula C12H21NO8S; molecular weight 339.36) is a sulfamate-substituted monosaccharide anticonvulsant developed at Johnson and Johnson and approved by the FDA in 1996 under the trade name Topamax. Mechanism is multifactorial: state-dependent sodium channel inhibition; GABA-A receptor potentiation at a non-benzodiazepine site; AMPA/kainate glutamate receptor antagonism; carbonic anhydrase inhibition (isozymes II and IV); high-voltage calcium channel inhibition. The carbonic anhydrase activity contributes to the characteristic adverse events: paresthesias (40 percent of patients), nephrolithiasis (1.5 percent), metabolic acidosis. Cognitive side effects are pronounced: word-finding difficulty, slowed mentation. Plasma half-life is 21 hours; metabolism is approximately 70 percent renal excretion unchanged. Approved for partial-onset and generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine prophylaxis, and (with phentermine, as Qsymia) chronic weight management. Used as the canonical multifactorial anticonvulsant and as a reference carbonic anhydrase inhibitor in CNS pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.